Innovative and Applied Emerging Technologies in Biospecimen Science (R21)
The summary for the Innovative and Applied Emerging Technologies in Biospecimen Science (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Innovative and Applied Emerging Technologies in Biospecimen Science (R21): Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exceptionally innovative, high risk, original and/or unconventional exploratory research projects focused on the inception and early stage development of highly innovative cancer-relevant technologies for biospecimen science. The overall goal is to develop and evaluate technologies capable of interrogating and/or maximizing the quality and utility of biospecimens for molecular analyses with minimal invasiveness or compromise to donor/patient health. This FOA will also support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. Projects must clearly demonstrate potential to produce a major impact in the area of biospecimen science.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-09-007. Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-09-005, that solicits applications under the NIH Exploratory/Developmental Phase II Research Grant (R33) award mechanism.
|Federal Grant Title:||Innovative and Applied Emerging Technologies in Biospecimen Science (R21)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-CA-09-004|
|Type of Funding:||Grant|
|CFDA Descriptions:||Cancer Construction|
|Current Application Deadline:||Sep 30, 2009|
|Original Application Deadline:||Sep 30, 2009|
|Posted Date:||Dec 15, 2008|
|Creation Date:||Dec 15, 2008|
|Archive Date:||Oct 31, 2009|
|Total Program Funding:||$1,000,000|
|Maximum Federal Grant Award:||$275,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Epigenetic Approaches in Cancer Epidemiology (R01)
- • Innovative and Applied Emerging Technologies in Biospecimen Science (R33)
- • Innovative Technology Development for Cancer Research (R21)
- • Application and Use of Transformative Emerging Technologies in Cancer Research (R33)
- • Application and Use of Transformative Emerging Technologies in Cancer Research (R21)
- • Small Grants Program for Cancer Epidemiology (R03)
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...